To systematically probe the biomarkers for response to DNA-PKcs inhibitors, we correlated the drug response profiles of NU7441 and the protein reverse phase (RPPA) dataset of TCPA (The Cancer Proteome Atlas) cancer cell line cohort (https://tcpaportal.org/), which identified several proteins whose expression is significantly correlated, negatively and positively, with the IC50 value of NU7441 (Figure 5C). Here, PRKDC is linked to cancer.